Abstract
Fremanezumab (Ajovy) is a new anti‐CGRP monoclonal antibody therapy indicated for the prophylaxis of migraine in adults. This article outlines its properties, efficacy, adverse effects and place in therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have